Alzinova AB (78D)
XFRA XFRA Primary Summary
Alzinova AB (78D) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alzinova AB ever had a stock split?
Alzinova AB Profile
| Biotechnology Industry | Healthcare Sector | Dr. Carol Routledge CEO | XFRA Exchange | SE0007413455 ISIN |
| Sweden Country | 5 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alzinova AB (publ) stands out as a pioneering biopharmaceutical entity deeply engaged in the conceptualization and advancement of immunotherapy treatments specifically targeting Alzheimer’s disease within Sweden. With its foundation in 2011 and operational base in Mölndal, Sweden, the company has dedicated its expertise and resources towards tackling this pervasive neurodegenerative condition. By harnessing advanced scientific approaches and focusing on innovative therapeutic solutions, Alzinova AB (publ) strives to make a meaningful impact in the lives of individuals affected by Alzheimer’s disease, offering hope through pioneering research and development efforts.
Products and Services
At the forefront of Alzinova AB (publ)’s ambitious ventures are two key developmental candidates, each representing a unique approach towards combating the pathological hallmarks of Alzheimer’s disease:
- ALZ-101: This candidate stands as an active therapeutic oligomer-specific vaccine, engineered with a precise focus on Alzheimer’s disease. At the core of ALZ-101’s design is the strategy to evoke an immune response specifically targeting the toxic oligomers implicated in the disease’s progression. Having completed part A of a phase 1b study, ALZ-101 exemplifies the company’s forward-thinking approach in actively engaging the body’s own defense mechanisms to fight Alzheimer's disease.
- ALZ-201: Embodied in ALZ-201 is a monoclonal antibody, crafted with the intent to neutralize the detrimental effects of toxic oligomers. This therapeutic agent represents a critical component of Alzinova AB (publ)’s arsenal in its battle against Alzheimer’s disease. Currently, the development process has ushered in a humanized variant of ALZ-201, aimed at patients suffering from Alzheimer's disease and is progressing through phase 1 clinical studies. Through ALZ-201, Alzinova AB (publ) aspires to forge a significant breakthrough in the therapeutic landscape, offering a beacon of hope to those grappling with this daunting ailment.
